Stem Cell Therapy International, Inc. Form 8-K/A August 14, 2008

## **UNITED STATES**

## **SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

# FORM 8-K/A

### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): AUGUST 14, 2008 (July 14, 2008)

# STEM CELL THERAPY INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada (State or other jurisdiction of 000-51931 (Commission File Number) 88-0374180 (I.R.S. Employer

**Identification No.)** 

incorporation or organization)

2203 N. Lois Avenue, 9th Floor, Tampa, FL 33607

1

### Edgar Filing: Stem Cell Therapy International, Inc. - Form 8-K/A

(Address of principal executive offices zip code)

#### (813) 600-4088

(Registrant s telephone number, including area code)

#### Not applicable

#### (former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

#### ITEM 4.01 CHANGES IN REGISTRANT S CERTIFYING ACCOUNTANT.

On July 14, 2008, Aidman, Piser & Company, P.A. ( Aidman Piser ) resigned as our independent registered public accounting firm. Aidman Piser s practice was acquired by Cherry, Bekaert & Holland, L.L.P. ( Cherry Bekaert ) in a transaction pursuant to which Aidman Piser merged its operations into Cherry Bekaert and certain of the professional staff and shareholders of Aidman Piser joined Cherry Bekaert either as employees or partners of Cherry Bekaert and will continue to practice as members of Cherry Bekaert.

The report of Aidman Piser regarding our financial statements for the fiscal years ended March 31, 2008 and March 31, 2007 does not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles, except that substantial doubt was raised as to our ability to continue as a going concern. During the past two years and during the period from the end of the most recently completed year through July 14, 2008, the date of resignation, there were no disagreements with Aidman Piser on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Aidman Piser would have caused them to make reference to such disagreements in its reports.

We provided Aidman Piser with a copy of this Report and the report filed on this Form 8-K/A prior to filing it with the Securities and Exchange Commission and requested that Aidman Piser furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether they agree with the statements set forth above, if they do not agree, the respects in which they do not agree. A copy of the letter, dated August 14, 2008, is filed as Exhibit 10.31 to this form.

On July 31, 2008 the Company engaged Brimmer, Burek, Keelan LLP, Certified Public Accountants, Tampa, FL, as its new independent accountants and who will audit the consolidated financial statements for the Company s Annual Report on Form 10K for the year ended March 31, 2009 and review the quarterly consolidated financial statements.

Exhibit:

10.31 Letter from Aidman Piser & Company, P.A.

#### SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEM CELL THERAPY INTERNATIONAL, INC.

By: /s/ Andrew J. Norstrud Name: Andrew J. Norstrud Title: Chief Financial Officer

Date: August 14, 2008